AstraZeneca’s Camizestrant Clears India’s SEC Review The Story: AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer wit...
Key Highlights: Implications: The expansion makes Turbhe more competitive for high-potency peptides, HPAPIs, and biomolecules, helping Piramal attract programs that need safe, sm...
